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2Abstract
A series of Mn(II) aminophosphonate complexes were successfully synthesized and
intercalated into the hydroxy double salt [Zn5(OH)8]Cl2·yH2O. Complex incorporation
led to an increase in the interlayer spacing from 7.8 to 10 – 12 Å. Infrared
spectroscopy showed the presence of the characteristic vibration peaks of the Mn(II)
complexes in the intercalates’ spectra, indicating successful incorporation. The
complex-loaded composites had somewhat lower proton relaxivities than the pure
complexes. Nevertheless, these intercalates may have use as MRI contrast agents for
patients with poor kidney function, where traditional Gd(III)-based contrast agents
cause severe renal failure.
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1. Introduction
Magnetic resonance imaging (MRI) is a powerful technique for the investigation of
soft tissue abnormalities. It has excellent spatial resolution, can be applied
non-invasively, and does not require potentially harmful ionizing radiation. However,
to obtain images of sufficient quality to permit a diagnosis to be made, a contrast
agent is needed to permit discrimination between different tissue types. To date,
Gd-based contrast agents have been effectively used to enhance the longitudinal (r1)
and transverse (r2) relaxation times of water protons, thus improving the clarity of
images obtained in magnetic resonance imaging (MRI). In patients with poor kidney
function - such as those suffering from chronic kidney disease - Gd(III)-based contrast
agents can lead to serious problems such as contrast-induced nephropathy [1] and
nephrogenic systemic fibrosis (NSF) [2, 3], which can both cause renal failure. This
arises because high doses of Gd-based contrast agents are required to obtain good
quality images.
3To ameliorate these issues, manganese species have been explored as alternative
contrast agents. The similarity of the ionic radii of Ca2+ and Mn2+ means that Mn2+
can effectively compete with Ca2+ in many biological systems, and the uptake of Mn2+
can allow the tracking and visualization of both the healthy and diseased central
nervous system [4, 5]. That said, caution is required because high-dose manganese
accumulated within the human body, especially in the brain, can cause a form of
Parkinsons’s disease (manganism) [6-8].
The Mn(II) complexes typically used are chelates such Mn(EDTA)(H2O) (Mangascan,
Mn(II) ethylenediaminetetraacetate) and Mn(DPDP) (Teslascan, Mn(II) dipyridoxal
diphosphate). A range of Mn aminophosphonate complexes has also been reported
[9], and found to have higher affinity for calcified tissues than aminocarboxylate
complexes. In addition, the analogous gadolinium aminophosphonate complexes
have previously been found to bind strongly to hydroxyapatite (one of the major
constituents of bone) [10].
The aim of chelation is to prevent the release of free Mn ions into the body, but the
low molecular weight species described above can lose Mn(II) relatively easily, and
dechelated Mn(II) ions can accumulate and lead to toxicity [11]. To preclude this, the
immobilization of the ions into larger systems has been proposed. Several studies
have explored this, for instance by incorporating MnO into colloidal particles [12, 13]
and mesoporous silica [14]. Mn(II) chelates have additionally been immobilized onto
a dendrimer structure [15].
Here, we adopted a different approach to prevent leaching. Many of the Mn(II)
complexes which can be used for MRI imaging – including the Mn
aminophosphonates – are capable of forming anions. They can thus be loaded into
solid state matrices by the technique of ion exchange. There exists a range of layered
4metal hydroxide (LMH) systems which have positively charged metal hydroxide layers
and interlayer anions which can be easily replaced by ion exchange, and these were
selected as host materials. One such family of materials, the layered double
hydroxides (LDHs, which typically contain a mixture of divalent and trivalent metal
cations) has formed the focus of several relevant investigations. In these, researchers
intercalated anionic contrast agents into the LDHs and found the resultant
composites to possess increased relaxivity [16] [17].
Hydroxy double salts (HDSs) comprise another family of LMHs, and have been much
less explored than LDHs: we are not aware of any reports investigating them for use
in MRI. They have the general formula [(M2+1-xM’2+1+x)(OH)3(1-y)]Xn-(1+3y)/n·zH2O, where
M2+ and M’2+ are divalent metals and Xn- is an exchangeable anion [18]. Here, we
used the biocompatible [Zn5(OH)8]Cl2·yH2O (Zn5-Cl) HDS as a host material. We first
synthesized and characterized a range of Mn(II) aminophosphonate complexes (MnL1,
MnL2, MnL3 and Mn2L42; see Figure 1). We then intercalated these into Zn5-Cl. Finally,
the proton relaxation properties of both the raw complexes and the complex-HDS
composites were evaluated.
Figure 1: The chemical structures of the ligands used in this work. (a) ethylene diamine
tetra(methylene phosphonic acid (L1), (b) hexamethylene diamine tetra(methylene phosphonic acid)
(L2), (c) xylene diamine tetra(methylene phosphonic acid) (L3), and (d) amino ethyl dimethylene
phosphonic acid (L4).
52. Materials and methods
2.1 Materials
Zinc chloride, zinc oxide and manganese (II) oxide were obtained from Sigma-Aldrich
UK. Sodium hydroxide tablets were procured from Fisher Scientific UK. All water used
was de-ionised prior to use. L1, L2 L3 and L4 were prepared according to the literature
method [10].
2.2 Methods
2.2.1 Synthesis of [Zn5(OH)8]Cl2·yH2O
The HDS ([Zn5(OH)8]Cl2·yH2O) was prepared by the reaction of 7.26 g (0.053 mol)
ZnCl2 and 3.00 g (0.037 mol) of ZnO in 18 ml deionized water. The dispersion was
stirred vigorously at room temperature for 7 days. The solid product was recovered
by vacuum filtration and washed with water. Finally the solid product was dried in air.
2.2.2 Synthesis of Mn(II) aminophosphonates [MnL1, MnL2, MnL3, Mn2(L4)2]
MnL1, MnL2, MnL3 and Mn2(L4)2 were prepared through reaction of the
polyaminophosphonate ligand and MnO (molar ratio 1 : 1). This process mirrors the
literature precedent for the analogous Gd(III) materials, but using MnO instead of
Gd2O3 [9, 10].
The successful formation of the Mn aminophosphonate complexes was verified by
elemental analysis and IR spectroscopy (Table 1).
6Table 1: Elemental analysis and IR data for the Mn complexes prepared in this work.
ID Formula
Elemental
contents / %
Obsd. (calcd.)a
Vibrational
frequency
(P=O/P-OH) / cm-1
MnL1 Mn(C6H18N2P4O12)(H2O)1.5
C: 14.61 (13.96)
H: 3.81 (4.10)
N: 5.61 (5.43)
H2O: 5.09 (5.24)
1139, 1047, 934
MnL2 Mn(C10H26N2P4O12)(H2O)1.3
C: 21.87 (21.12)
H: 4.68 (5.07)
N 5.19 (4.93)
H2O: 4.16 (4.12)
1149, 1057, 907
MnL3 [Mn(C12H22N2P4O12)(H2O)1.9][MnO]1.5
C: 20.35 (20.72)
H: 3.42 (3.68)
N: 4.31 (3.97)
H2O: 4.93 (4.85)
1153, 1083, 917
Mn2(L
4)2 Mn2(C4H11NP2O)2(H2O)1.5
C: 15.43 (15.34)
H: 4.33 (4.51)
N: 4.57 (4.47)
H2O: 8.47 (8.63)
1183, 1050, 917
a C, H, and N contents were determined by elemental microanalysis, and the water content estimated
from thermogravimetric analysis assuming that the first stage of mass loss arose from dehydration.
The stages of mass loss were not always clear however, and thus some uncertainty surrounds these
numbers.
2.2.3 Ion exchange intercalation
The [Zn5(OH)8]Cl2·yH2O (Zn5-Cl) host material (0.2 mmol) was suspended in 5 mL of
an aqueous solution containing 0.04 mmol of a Mn complex (L1, L2, L3 and (L4)2) and
0.08 mmol (a two-fold molar excess with respect to Mn) of NaOH. The suspension
was stirred at 60 °C for 7 days. The resultant suspension was transferred to a
centrifuge tube and spun at 2000 rpm for 6 minutes. The supernatant was discarded.
The solid was washed with water, re-suspended and centrifuged again, with this
process repeated in total three times. The solid product was dried in an oven at
approximately 30 °C for 24 h. To explore the effect of the reaction parameters,
additional samples were prepared with variations in the amount of Mn complex
(0.04, 0.08, 0.12 mmol) and volume of water used (1, 2, 5, 10 mL). All other reaction
conditions were kept constant.
72.3 Characterization
2.3.1 Powder X-ray diffraction
X-ray diffraction patterns were recorded over the 2θ range from 3.5 to 40 °on a 
powder diffractometer (PW 1830/40, Philips, Amsterdam, Netherlands) using Cu Kα 
radiation at 40 kV and 25 mA.
2.3.2 Fourier transform infrared (FTIR) spectroscopy
FTIR analyses were carried out on a Spectrum 100 instrument (PerkinElmer Co. Ltd,
Waltham, MA, USA) over the range 650 – 40000 cm-1 at a resolution of 4 cm-1.
2.3.3 Thermogravimetric analysis
Thermogravimetric analysis (TGA) was undertaken with the aid of a Discovery
analyser (TA Instruments, New Castle, DE, USA). Approximately 3 – 4 mg of a sample
was loaded into an open aluminium pan and then heated at 10 °C min-1 from 30 to
300 °C. Experiments took place under a flow of N2 gas (25 mL min-1).
2.3.4 Elemental microanalysis
C, H, and N contents were determined using the combustion method on a Flash 2000
Elemental Analyser (Thermo Scientific, Waltham, MA, USA).
2.3.5 Microwave plasma-atomic emission spectroscopy
The Mn content of the intercalation compounds was determined by microwave
plasma-atomic emission spectroscopy (MP-AES; 4100 instrument, Agilent
Technologies, Santa Clara, California, USA). 10 mg of the sample was placed in a 50
mL volumetric flask and digested in diluted nitric acid (0.5 %). Mn emission was
measured for the lines at 257.610 [Mn(II)], 259.372 [Mn(II)], and 403.076 nm [Mn(I)].
Calibration was performed over the range is 1.56 – 100 ppm.
2.3.6 X-ray fluorescence
The Zn : Mn ratio in the intercalates was determined for selected samples using
8X-ray fluorescence (XRF). Samples were finely ground before measurement and
placed onto clingfilm. A glass slide was used to flatten the powders, and the samples
were then placed onto the fluorimeter (X-Met 3000TXR+, Oxford Instruments,
Abingdon, UK) for measurement.
2.3.7 In vitro release studies
Approximately 10 mg of the intercalation compound was placed in 20 mL of a
phosphate buffered saline (PBS; pH 7.4) buffer and incubated at 37 °C under stirring
at 100 rpm. 10 mL aliquots were withdrawn from the buffer at predetermined time
points and replaced by 10 mL of fresh buffer to maintain a constant volume. The
aliquots were centrifuged (2000 rpm, 6 minutes; 5804R centrifuge, Eppendorf,
Hauppauge, NY, USA) and the Mn complex content in the resultant supernatant
quantified by UV-vis spectroscopy (Cary 100 spectrophotometer, Agilent
Technologies, Santa Clara, California, USA). Each experiment was repeated three
times, and results are reported as mean ± S.D.
2.3.8 Proton relaxivity measurements
Measurements of the longitudinal (T1) and transverse (T2) relaxation times of water
protons were carried out on a Bruker Minispec mq20 relaxometer (20 MHz, 0.47 T,
Bruker Corporation, Billerica, MA, USA) at 37 °C, using inversion recovery and CPMG
pulse sequences, respectively. 5 mg of the sample was placed in a 10 mm-diameter
NMR tube and held using 1 mL of 1% agarose.
3. Results
3.1 X-ray diffraction
XRD patterns for the Zn5-Cl HDS and the intercalation compounds Zn5-MnL1,
Zn5-MnL2, Zn5-MnL3 and Zn5-Mn2(L4)2 are shown in Figure 2. Clear evidence of partial
intercalation can be seen.
9Figure 2: X-ray diffraction patterns of Zn5-MnL
1, Zn5-MnL
2, Zn5-MnL
3, Zn5-Mn2(L
4)2, with the intercalate
reflections marked *.
The interlayer spacing in the Zn5-Cl HDS is 7.8 Å. After reaction with Mn complexes,
the most intense reflections become broader and less intense compared with the
pristine Zn5-Cl material, suggesting partial intercalation of the complexes in some
interlayer spaces. In addition, a new set of weak Bragg reflections emerges at lower
angle. These arise over the angular range from ca. 9 to ca. 10° for Zn5-MnL1, 7.5° for
Zn5-MnL2, 8.1/ 9.1° for Zn5-MnL3 and 8.8 / 9.1° for Zn5-Mn2(L4)2. These reflections are
marked * in Figure 2. These reflections correspond to an increase in the interlayer
spacing to 10 - 12 Å. These reflections are attributed to the formation of Zn5-complex
intercalates. Notably, there are two distinct sub-10° reflections in Zn5-MnL3 and
Zn5-Mn2(L4)2, as detailed in Table 2. This may be caused by the adoption of different
arrangements of [MnL3]2- and [Mn2(L4)2]2- in the interlayer regions. In all the patterns
of Mn chelate-loaded HDSs, a reflection corresponding to unexchanged chloride
appears at ca. 11°.
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Table 2: X-ray diffraction data for Zn5-Mn complex.
Sample
Reaction molar ratio
Zn5-Cl : Mn complex
1st guest d003 / Å 2
nd guest d003 / Å
Zn5-MnL
1 5 : 1 [MnL1]2- 9.7 Cl- 7.7
Zn5-MnL
2 5 : 1 [MnL2]2- 11.9 Cl- 7.8
Zn5-MnL
3 5 : 1 [MnL3]2- 9.7 / 11.2 Cl- 7.8
Zn5-Mn2(L
4)2 5 : 1 [Mn(L
4)2]
2- 9.7 / 10.1 Cl- 7.8
3.2 IR spectroscopy
The IR spectra of the intercalation compounds are presented in Figure 3.
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Figure 3: IR spectra of Zn5-Cl HDS, Zn5-MnL
1, Zn5-MnL
2, Zn5-MnL
3, and Zn5-Mn2(L
4)2, together with
those of the unreacted complexes.
The intense band located at 3450 cm-1 in the spectrum of Zn5-Cl is associated with
stretching vibrations of OH groups in the layers. A small water absorption band
(originating from the delta bend) is at 1607 cm-1. The bands below 1040 cm-1 are
attributed to Zn-O vibrational bending.
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Characteristic PO3 bands can be seen in the region of 1200 cm-1 – 900 cm-1 after the
Mn complexes are incorporated into Zn5-Cl, confirming their successful intercalation.
These peaks shift from 1047/934 cm-1 (v(P=O), v(P-O(H))) in MnL1 to 1043/901 cm-1
in Zn5-MnL1, 1057/907 cm-1 in MnL2 to 1043/901 cm-1 in Zn5-MnL2, 1083/917 cm-1 in
MnL3 to 1086/907 cm-1 in Zn5-MnL3 and 1050/917 cm-1 in Mn2(L4)2 to 1043/904 cm-1
in Zn5-Mn2(L4)2 due to electrostatic and hydrogen bonding interactions between the
P=O groups and HDS layers.
3.3 Elemental analysis
XRF data were used to determine the Zn : Mn ratio in the intercalates: the results are
shown in Table 3. The Mn(II) complex contents were calculated to be approximately
10 wt% in the composites.
Table 3: XRF data for Mn complex intercalates
Sample Zn : Mn molar ratio Proposed formula
Zn5-MnL
1 5 : 0.069 [Zn5(OH)8]Cl1.862(MnC6H17N2P4O12)0.069·2H2O
Zn5-MnL
2 5 : 0.079 [Zn5(OH)8]Cl1.842(MnC10H26N2P4O12)0.079·2H2O
Zn5-MnL
3 5 : 0.074 [Zn5(OH)8]Cl1.852(MnC12H22N2P4O12)0.074·2H2O
Zn5-Mn2(L
4)2 5 : 0.063 [Zn5(OH)8]Cl1.936 (Mn2(C4H11NP2O6)2)0.032·2H2O
3.4 Mn(II) complex release
Zn5-MnL3 was taken as an examplar system to explore the rate of complex release
from the intercalates. The UV-vis spectrum of MnL3 shows absorbances at 209 and
248 nm, while those of L3 and its dianion contain peaks at 212 / 265 nm and 211 /
265 nm respectively. Analysis of the release aliquots reveals that absorbance peaks
arise at 207 and 247 nm. There is no absorbance at 265 nm (data not shown). It is
thus clear that the entity released is the MnL3 complex, and that there is no
separation of the Mn(II) ion and the ligand.
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Having established this, the release of MnL3 from Zn5-MnL3 was quantified as a
function of time using the peak at 247 nm (Figure 4).
Figure 4: The release profile of MnL3 from Zn5-MnL
3. Data are shown as mean ± S.D. from three
independent experiments.
There is initially a burst of release of MnL3 (ca. 20 %) from the complex during the
first 6 h of the experiment. This is followed by more gradual release reaching ca. 30 %
after 24 h. These findings are very similar to those found in the literature for Gd
complex intercalates of HDSs [19]. The burst effect is attributed to the external
adsorption of some Mn(II) complex on the HDS surface. The subsequent release is
thought to result from ion-exchange between the anions in the interlayer and
phosphate anions in the buffer. This is a much slower process than release from the
surface due to the strong electrostatic interactions which exist between the HDS
layer and the MnL3 complex. Given that only 30 % of the incorporated Mn(II)
complex is freed after 24 h, it is thus clear that the intercalates have a high degree of
stability under physiological conditions, and Mn(II) leakage is not a significant
concern.
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3.5 Proton relaxivities
The longitudinal (r1) and transverse (r2) relaxivities (relaxation rate enhancement per
mM metal ion concentration) of the Mn(II) complex intercalates, together with
controls, are listed in Table 4.
Table 4: Proton relaxivities of the Mn complexes and their intercalates.
Sample [Mn] /mM T1 / ms T2 / ms r1 / s-1mM-1 r2 / s-1mM-1
Agarose gel 3200.00 ± 100 107.00 ± 2.00
Zn5-Cl 3000.00 ± 10.0 140.00 ± 2.00
MnL1 1.00 380.23 ± 1.21 56.15 ± 0.13 2.63 ± 0.02 17.81 ± 0.05
MnL2 1.00 303.95 ± 1.71 50.18 ± 0.08 3.29 ± 0.03 19.93 ± 0.03
MnL3 1.13 454.13 ± 0.42 57.77 ± 0.05 1.95±0.002 15.32 ± 0.01
Mn2(L
4)2 0.74 87.80 ± 0.26 15.11 ± 0.04 15.39±0.05 89.41 ± 0.24
Zn5-Cl + MnL
1 a 1.00 666.67 ± 0.49 62.66 ± 0.05 1.50±0.003 15.96 ± 0.01
Zn5-Cl + MnL
2 a 1.00 1960.78 ± 5.00 75.38 ± 0.40 0.51±0.002 13.27 ± 0.04
Zn5-Cl + MnL
3 a 1.00 1449.30 ± 2.04 81.07 ± 0.35 0.69±0.01 12.32 ± 0.005
Zn5-Cl +Mn2(L
4)2
a 0.90 99.62 ± 0.80 17.56 ± 0.08 11.1± 0.09 63.26 ± 0.28
Zn5-MnL
1 0.83 1019.83 ± 13.20 69.32 ± 0.07 1.19 ± 0.02 17.43 ± 0.02
Zn5-MnL
2 0.92 1369.50 ± 2.12 72.22 ± 0.06 0.79 ± 0.46 15.02 ± 0.01
Zn5-MnL
3 1.00 1479.50 ± 2.12 91.98 ± 0.16 0.67 ± 0.40 10.85 ± 0.02
Zn5-Mn2(L
4)2 0.35 265.20 ± 0.20 48.43 ± 0.02 10.8±0.004 58.99 ±0.004
a These materials are physical mixtures of the two components.
Relaxivities were obtained by measuring the paramagnetic longitudinal and
transverse relaxation times and comparing these to the Mn concentrations
(determined through microwave plasma-atomic emission spectroscopy). The
relaxation times of the diamagnetic Zn5-Cl HDS (T1 = 3000 ms, T2 = 140 ms) and
agarose gel (T1 = 3200 ms, T2 = 107 ms) when compared to those of water (T1 = 2700
ms, T2 = 3400 ms) show no change in the water proton T1 relaxation process. There is
a small but non-negligible decrease of T2 due to the relative immobilization of water
molecules in the diamagnetic agarose gel and at the surface of the Zn5-Cl HDS.
The proton relaxivities of paramagnetic metal complexes may result from
inner-sphere, second-sphere and outer-sphere contributions [20, 21]. The number of
water molecules in the first hydration sphere is very important in determining the
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size of the inner-sphere contribution. However, the contribution of water molecules
present for long lifetimes in the second-sphere of complexes can also be significant
[22, 23]. This is particularly true for polyaminophosphonate complexes, due to
hydrogen bonding of water molecules with the phosphonate oxygens [24]. This effect
is even more noticeable in phosphonate complexes with no inner-sphere water, such
as Gd(DOTMP)5- (DOTMP = 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetrakis(methylphosphonic acid) and other Gd(II) tetraazaphosphonate and
phosphinate complexes [25].
Oakes et al. have developed a method to determine the number of inner sphere
water molecules (q) from water proton relaxation rates (r1) of aqueous solutions of
paramagnetic complexes [26]. Assuming that Mn2+(aq) has a q value of 6, a value of q
= 0.99 was obtained for[Mn(EDTA)]2-, indicating that in solution the coordination
sphere of Mn2+ is expanded to a coordination number of 7, with one inner-sphere
water molecule [26]. This observation was in agreement with the X-ray crystal
structure of the same complex [27] and further confirmed by proton nuclear
magnetic relaxation dispersion studies [28]. The same technique was applied to MnL1,
giving a value of q = 1.20; this was corrected to q = 1.32 or 1.44 assuming one or two
unbound phosphonate groups at a time [26]. However this latter calculation might
overestimate the q value, as it did not take into account the possible contribution of
second sphere relaxation.
We found that MnL1 has 2.63 mM-1 s-1 for r1 and 17.81 mM-1 s-1 for r2 at 20 MHz and
37 °C (Table 4). The former is very similar to the reported r1 value of the analogous
[Mn(EDTA)(H2O)]2- species (2.9 s-1 mM-1 at 20 MHz, 37 °C) which has q = 1 and a
negligible second sphere relaxation contribution [29, 30]. Taking into account the
significant second-sphere contribution expected, our results for MnL1 point to a q
value between 1 and 0. This is less than the water content observed by TGA, but it is
very likely that not all the water evolved during heating is present in the inner sphere
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of Mn(II).
The increase in the length of the linear aliphatic chain connecting the N atoms going
from L1 to L2 (Figure 5) slightly increased the relaxivities of the MnL2 complex (to r1 =
3.29 mM-1s-1, r2 = 19.93 mM-1s-1). This is probably due, in part, to the increased size
of the compound leading to a slower tumbling time [9].
Figure 5: The aliphatic chains connecting the N atoms in L1 and L2.
However, the structure of the L2 ligand is such that steric hindrance may prevent the
simultaneous co-ordination of all six donors groups to the metal ion, increasing the
value of q, which also would contribute to the observed r1 increase. This is in
agreement with the observation that MnL2 is less stable than MnL1 [31]. The complex
structure proposed in the literature (see Figure 6) for the complex with only two
nitrogen atoms and one phosphonate group chelated to Mn(II) forming a stable cyclic
structure is highly improbable, as it would imply a q value too high to be compatible
with the observed r1 [31].
Figure 6: The proposed cyclic structure of MnL2.
There is evidence that aminophosphonate ligands with two or more phosphonate
groups have lower coordination tendencies than expected due to the mutual
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repulsion between adjacent binegative phosphonate groups [32, 33]. This is reflected
in the stability constants of the MnL1 and MnL2, which are smaller than those of the
corresponding carboxylate analogues EDTA and HDTA [31]. Therefore, the tendency
to have some unbound phosphonate group may increase as their number increases
in the ligand, with the resultant possibility of higher q values.
MnL3 has previously been reported to have better relaxation than MnL1 at 10 MHz
and 37 °C (10 mM-1 s-1 vs. 3.7 mM-1 s-1), thought to be because the introduction of
the aromatic ring increased the molecular weight [9]. However, in this work, at 20
MHz and 37 °C MnL1 (r1 = 2.63 mM-1 s-1) gives faster relaxation than MnL3 (r1 = 1.95
mM-1 s-1). This can be explained because the steric crowding of MnL3 prevents the
binding of inner water or restricts the exchange of bound water protons [34].
Among the four Mn complexes, Mn2(L4)2 shows the most effective relaxation. This is
believed to be a result of it having a flexible structure (see Figure 7). This structure
can lead to the wrapping of two Mn2+ ions by two L4 ligands, with a bridging water
molecule, giving a coordination number of six for each Mn. This structure is
consistent with the elemental analysis and TGA data. It is thought to give an
increased number of inner sphere water molecules and therefore leads to the
increased relaxivities attained.[34]
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Figure 7: The proposed structure of Mn2(L
4)2.
The analogous Gd complexes have previously been studied in detail at 10 MHz and
37 °C [10]. The Mn complexes generally have lower values for r1 but slightly higher
values for r2: GdL1- had r1 = 11.1 mM-1s-1 and r2 = 15.9 mM-1s-1, while GdL3 showed r1 =
10.0 mM-1s-1 and r2 = 14.3 mM-1s-1 (at 10 MHz and 37 °C) [10]. This is expected to
arise because there is a much more important scalar contribution to r2 in the case of
Mn(II) complexes, while the scalar contribution to r1 is very small, especially for Gd(III)
complexes (where dipole-dipole interactions are dominant) [20, 21]. Such a scalar
contribution to r2 increases drastically at high magnetic fields due to the field
dependence of the electron spin relaxation time (S), which rises sharply at high
fields. In addition, the presence of a non-dispersive S term in the equation for the
contact relaxation causes r2 to become proportional to S at high fields, and thus to
increase steadily [20].
The Mn complex intercalates showed lower relaxivities than their physical mixture
counterparts (see Table 4Table 4). These decreased relaxivities probably result from
reduced hydration numbers. Steric compression in the interlayer might eliminate
water molecules from the inner coordination sphere, meaning that in the intercalates
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no water molecule is directly coordinated to the Mn complexes [35]. Low
longitudinal relaxivities could arise from co-intercalated chloride ions exchanging
with water molecules bound to Mn(II). In addition, HDSs have very high affinity for
carbonate ions, and thus small amounts of dissolved carbon dioxide can lead to the
incorporation of CO32- into the interlayer space. This too could displace inner sphere
water molecules from the Mn complexes.
3.6 Variation of intercalation conditions
In attempts to enhance the relaxivity, a number of experiments were performed in
which the intercalation conditions were systematically varied. The molar ratio of
Zn5-Cl to Mn complex was varied from 5:1 to 5:2 and 5:3, and the volume of water
used for experiments changed from 5 mL to 10, 2, and 1 mL. This led to a series of 12
intercalates for each complex.
In general, there is no noticeable effect of varying the HDS : guest ratio or the
amount of water used for reaction on the interlayer spacing or the extent of reaction
(see Supplementary Information Tables S1 to S4). The exception to this is with MnL1,
where intercalation could only be clearly seen for the sample reported above. Taking
Zn5-MnL2 as an example (Figure 8), it is clear that changing the volume of water used
does not affect the crystallinity of the product. Increasing the amount of guest used
in the reactions (e.g. going from a 5:1 to 5:3 molar ratio) does in some cases result in
an increase in the intensity of the intercalate reflection, but this is not a universal
observation.
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Figure 8: The effect of varying the reaction parameters on the low-angle XRD patterns of Zn5- MnL
2
intercalates. The ratio indicated is the HDS : Mn complex ratio used for intercalation.
The similarity of the intercalation compounds, regardless of the guest excess and
water volume used, is reflected in their r1 and r2 values (see Table S5), which are all
relatively similar. These are illustrated in Figure 9. It can be seen that there are no
major trends resulting from variation in reaction parameters. In terms of the r1 values,
the Zn5-Mn2(L4H1)2 systems give continually higher values than the Zn5-Mn(L3H4) or
Zn5-Mn(L2H4) materials, with a maximum value of 17.12 mM-1s-1. There are no clear
trends in the r2 data, but from a suitable choice of parameters it is possible to obtain
r2 values as high as 68.31 mM-1s-1. This r1 value is two-fold higher than that reported
for a Mn(II)-based dendrimer containing six tyrosine-derived [Mn(EDTA)(H2O)]2- units
conjugated with a cyclotriphosphazene core (r1 = 8.2 s-1mM-1 at 20 MHz).[15]
21
(a) (b)
Figure 9: The (a) r1 and (b) r2 values obtained for the Mn complex intercalates as a function of reaction
conditions. Symbols are as follows:  Zn5-MnL
2, 10 mL water; Zn5-MnL
2, 5 mL water; Zn5-MnL
2, 2
mL water; Zn5-MnL
2, 1 mL water;  Zn5-MnL
3, 10 mL water; Zn5-MnL
3, 5 mL water; Zn5-MnL
3,
2 mL water;  Zn5-MnL
3, 1 mL water;  Zn5-Mn2(L
4)2, 10 mL water;  Zn5-Mn2(L
4)2, 5mL water; 
Zn5-Mn2(L
4)2, 2 mL water; Zn5-Mn2(L
4)2, 1 mL water.
The results observed here in general accord well with the literature. The
incorporation of MnO into colloidal particles [12] and mesoporous silica [14] also
resulted in low relaxivities (r1 = 0.37 s-1 mM-1 and r2 = 1.74 s-1 mM-1; r1=0.99 s-1 mM-1
and r2 = 11.02 s-1 mM-1 respectively). Nevertheless, the previously reported systems
still showed the ability to selectively enhance breast cancer cells in T1-weighted MRI
[12], or to label and track mesenchymal stem cells [14]. Thus, it seems likely that the
Mn complex / HDS composites prepared in this work will also have utility as contrast
agents. The advantage of the HDS-based materials is that the embedded Mn(II) is
chelated (unlike the MnO systems), and therefore they are expected to have much
reduced toxicity.
4. Conclusions
A series of Mn(II) chelation complexes was synthesised and fully characterized. They
were subsequently loaded into the hydroxy double salt (HDS) [Zn5(OH)8]Cl2·2H2O
(Zn5-Cl). Successful preparation of HDS/Mn chelate composites was confirmed by
X-ray diffraction, IR spectroscopy, X-ray fluorescence (XRF), and microwave
plasma-atomic emission spectroscopy (MP-AES). The interlayer spacing was observed
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to increase from 7.8 Å with Zn5-Cl HDS to 10 – 12 Å for the intercalates. The
characteristic absorption bands of the Mn(II) complexes were clearly visible in the IR
spectra of the intercalates, indicating the encapsulation of intact Mn(II) complexes in
the Zn5-HDS. The presence of Mn was unequivocally demonstrated by XRF and
MP-AES measurements. The longitudinal relaxivities of the complexes after
intercalation showed somewhat lower values compared with the pure complexes
and physical mixtures of the complexes and HDS, probably because of steric
crowding and/or carbonate exchange leading to no inner-sphere water being bound
to the Mn(II) centre. Nevertheless, the r1 and in particular the r2 values are still
sufficient to give the HDS/Mn complex composites potential utility as contrast
agents.
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